Advisory board · Prof. Benedikt Fischer

23 Mar 2026 · Phone · Prof. Benedikt Fischer, Charité Berlin · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0091—

Capture insight from this engagement

Location: Osaka University Hospital
Therapeutic area: Oncology
Country: Germany
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

PD-L1 testing turnaround
Brain-metastasis subgroup data
Duration of response

Scientific content used

VTX core scientific deck v3.2
PD-L1 testing pathway infographic

Questions raised

Is there subgroup data for patients with untreated brain metastases?

Notes

Advisory board with pathologist at Osaka University Hospital. Discussed pd-l1 testing turnaround, brain-metastasis subgroup data, duration of response.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Connect with Clinical Development

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 2
Depth of exchange: 2
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0091

Audit history (0)

All create, update and approval events for this record

No audit events in sample data